Skip to content
10-Q

Quarterly Report

CG Oncology, Inc. CGON

0001193125-26-214669

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 6, 2026 88.2M sh
Shares Diluted Q1 2026 · Mar 31, 2026 84.52M sh
Shares Diluted Q1 2026 · Mar 31, 2025 76.19M sh
Capex Q1 2026 · Mar 31, 2026 $304K
Capex Q1 2026 · Mar 31, 2025 $16K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$56.94M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$29.28M
Long Term Debt Q1 2026 · Mar 31, 2026 $3M
Long Term Debt Q1 2026 · Dec 31, 2025 $3M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $33.7M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $32.49M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.09B
Stockholders Equity Q1 2026 · Dec 31, 2025 $752.6M
Stockholders Equity Q1 2026 · Mar 31, 2025 $704.76M
Stockholders Equity Q1 2026 · Dec 31, 2024 $733.38M
Current Liabilities Q1 2026 · Mar 31, 2026 $35.22M
Current Liabilities Q1 2026 · Dec 31, 2025 $30.84M
Total Liabilities Q1 2026 · Mar 31, 2026 $43.48M
Total Liabilities Q1 2026 · Dec 31, 2025 $38.99M
Current Assets Q1 2026 · Mar 31, 2026 $1.1B
Current Assets Q1 2026 · Dec 31, 2025 $759.48M
Total Assets Q1 2026 · Mar 31, 2026 $1.14B
Total Assets Q1 2026 · Dec 31, 2025 $791.59M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.71
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.45
Eps Basic Q1 2026 · Mar 31, 2026 −$0.71
Eps Basic Q1 2026 · Mar 31, 2025 −$0.45
Sga Expense Q1 2026 · Mar 31, 2026 $20.78M
Sga Expense Q1 2026 · Mar 31, 2025 $14.79M
Rd Expense Q1 2026 · Mar 31, 2026 $43.73M
Rd Expense Q1 2026 · Mar 31, 2025 $27.47M
Net Income Q1 2026 · Mar 31, 2026 −$60.2M
Net Income Q1 2026 · Mar 31, 2025 −$34.45M
Operating Income Q1 2026 · Mar 31, 2026 −$66.39M
Operating Income Q1 2026 · Mar 31, 2025 −$42.2M
Revenue Q1 2026 · Mar 31, 2026 $1.08M
Revenue Q1 2026 · Mar 31, 2025 $52K